Ticker League

EBITDA for Boston Scientific (BSX)

Latest filings through · Reported

Metric

TTM

$4.94B

YoY change

-5.2%

5Y CAGR

+19.8%

Peak year (2024)

$3.94B

EBITDA history chart for Boston Scientific (BSX) from 1991 to 2025

Latest: $3.73B

EBITDA growth chart for Boston Scientific (BSX) from 1991 to 2025

Latest: -5.2%

EBITDA history table for Boston Scientific (BSX) from 1991 to 2025

  • 2025$3.73B-5.2%
  • 2024$3.94B+14.0%
  • 2023$3.45B+26.0%
  • 2022$2.74B+8.9%
  • 2021$2.52B+66.6%
  • 2020$1.51B-31.6%
  • 2019$2.21B-14.5%
  • 2018$2.58B+28.8%
  • 2017$2.01B+63.7%
  • 2016$1.23B+240.6%
  • 2015$360.00M-16.9%
  • 2014$433.00M-39.9%
  • 2013$721.00M-122.8%
  • 2012−$3.16B-293.3%
  • 2011$1.64B+997.3%
  • 2010$149.00M-238.0%
  • 2009−$108.00M-84.5%
  • 2008−$699.00M-174.4%
  • 2007$940.00M-140.5%
  • 2006−$2.32B-279.1%
  • 2005$1.29B-29.4%
  • 2004$1.83B+97.1%
  • 2003$930.00M+8.6%
  • 2002$856.00M+39.4%
  • 2001$614.00M-28.3%
  • 2000$856.00M-5.2%
  • 1999$903.00M+45.6%
  • 1998$620.00M+21.8%
  • 1997$509.00M+23.6%
  • 1996$411.80M+37.3%
  • 1995$299.90M+115.8%
  • 1994$139.00M+20.9%
  • 1993$115.00M+18.1%
  • 1992$97.40M+31.8%
  • 1991$73.90M—

EBITDA values are taken from Boston Scientific's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Boston Scientific (BSX)

According to Boston Scientific's latest reported financial statements, the company's current EBITDA (TTM) is $4.94B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

Boston Scientific (BSX) most recent annual EBITDA stands at $3.73B (2025) – declined 5.2% year-over-year.

Over 2020–2025 (5 years), Boston Scientific EBITDA expanded at a +19.8% compound annual rate, with mixed annual results across the window.

Between 2024 and 2025, Boston Scientific EBITDA declined 5.2%, falling from $3.94B to $3.73B.

Across the available history, EBITDA reached its high of $3.94B in 2024 and its low of −$3.16B in 2012.

Boston Scientific EBITDA by Year

Boston Scientific EBITDA 2025: $3.73B

Boston Scientific posted EBITDA of $3.73B in 2025, declined 5.2% below 2024.

Boston Scientific EBITDA 2024: $3.94B

In 2024, Boston Scientific reported EBITDA of $3.94B, grew 14.0% from 2023. This figure represents the highest annual value in the available history.

Boston Scientific EBITDA 2023: $3.45B

Boston Scientific EBITDA in 2023 was $3.45B, grew 26.0% from 2022.

Boston Scientific EBITDA 2022: $2.74B

2022's EBITDA for Boston Scientific came in at $2.74B, grew 8.9% from 2021.

Boston Scientific EBITDA 2021: $2.52B

Boston Scientific EBITDA in 2021 was $2.52B.

See more financial history for Boston Scientific (BSX).

Sector peers by EBITDA

Healthcare peers of Boston Scientific (BSX), ranked by their latest EBITDA

Frequently asked questions

Boston Scientific (BSX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview